Holen Sie sich die Stockscreener-App
2.861
1.22%
-0.019
Schlusskurs vom Vortag:
$2.88
Offen:
$2.9
24-Stunden-Volumen:
8,023
Relative Volume:
0.03
Marktkapitalisierung:
$77.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-49.81M
KGV:
-1.327
EPS:
-2.156
Netto-Cashflow:
$-42.93M
1W Leistung:
+9.42%
1M Leistung:
+25.33%
6M Leistung:
-38.69%
1J Leistung:
-81.49%
1-Tages-Spanne:
$2.8508
$2.91
1-Wochen-Bereich:
$2.53
$3.05
52-Wochen-Spanne:
$1.60
$15.83
Alto Neuroscience Inc Stock (ANRO) Company Profile
Firmenname
Alto Neuroscience Inc
Sektor
Branche
Telefon
773-255-5012
Adresse
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Vergleichen Sie ANRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
2.861 | 69.85M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.50 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.51 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.08 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.96 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.96 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-23 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-09-03 | Eingeleitet | Wedbush | Outperform |
| 2024-02-27 | Eingeleitet | Jefferies | Buy |
| 2024-02-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-27 | Eingeleitet | Stifel | Buy |
| 2024-02-27 | Eingeleitet | TD Cowen | Outperform |
| 2024-02-27 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
Biotech Bargain Or Bust? Alto Neuroscience Faces Trial Test - Finimize
What makes Alto Neuroscience Inc. stock price move sharplyROI Focused Stock Calls - beatles.ru
Why Alto Neuroscience Inc. stock attracts strong analyst attentionFree Consultation - Newser
How Alto Neuroscience Inc. stock performs during market volatilityFree Stock Market Trend Analysis - Newser
Alto Neuroscience reprices employee stock options to $2.35 per share - Investing.com
Alto Neuroscience to advance depression drug after promising study By Investing.com - Investing.com South Africa
Alto Neuroscience (NYSE:ANRO) Receives Buy Rating from HC Wainwright - Defense World
Alto Neuroscience Identifies Biomarker in Phase 2 Trial for Major Depressive Disorder Patients - MarketScreener
Alto Neuroscience identifies biomarker, reports ALTO-203 pharmacodynamic results - TipRanks
Bank of America Corp DE Buys 22,007 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience : Corporate Presentation - marketscreener.com
Two Sigma Investments LP Has $130,000 Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
H.C. Wainwright Affirms Buy Rating on Alto Neuroscience (ANRO), Sets $10 PT - MSN
Jane Street Group LLC Increases Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Wellington Management Group LLP Boosts Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Consensus Target Price from Analysts - Defense World
Nuveen Asset Management LLC Reduces Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
H.C. Wainwright maintains buy rating on Alto Neuroscience stock By Investing.com - Investing.com Canada
Alto Neuroscience acquires novel TRD treatment candidate By Investing.com - Investing.com South Africa
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal - Yahoo
Alto Neuroscience, Inc. acquired Novel Dopamine Agonist Combination Product Candidate from Chase Pharmaceuticals Corporation, Inc. - MarketScreener
Strategic Acquisition and Promising Clinical Developments Drive Buy Rating for Alto Neuroscience, Inc. - TipRanks
Alto Neuroscience Acquires Assets from Chase Therapeutics - TipRanks
Alto Neuroscience acquires dopamine agonist combination candidate - TipRanks
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway - Yahoo Finance
BNP Paribas Financial Markets Has $180,000 Stake in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience reports progress in depression drug trials By Investing.com - Investing.com South Africa
Alto Neuroscience, Inc. Presents Data At the 2025 American Society of Clinical Psychopharmacology Annual Meeting - marketscreener.com
Alto Neuroscience reports progress in depression drug trials - Investing.com India
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder - Business Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
Northern Trust Corp Acquires 390,190 Shares of Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
HC Wainwright Issues Pessimistic Outlook for ANRO Earnings - Defense World
Q2 Earnings Forecast for Alto Neuroscience Issued By Wedbush - Defense World
Alto Neuroscience, Inc.: Promising Clinical Trials and Strong Financial Position Justify Buy Rating - TipRanks
Equities Analysts Set Expectations for ANRO Q1 Earnings - Defense World
Wedbush Reiterates Neutral Rating for Alto Neuroscience (NYSE:ANRO) - Defense World
Alto Neuroscience Advances Precision Psychiatry Pipeline - TipRanks
Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights - marketscreener.com
Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. (NYSE:ANRO) Shares Acquired by Barclays PLC - Defense World
Alto Neuroscience, Inc. (NYSE:ANRO) Receives $15.40 Average Target Price from Brokerages - Defense World
Stifel Financial Corp Takes $544,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Trading Day Triumph: Alto Neuroscience Inc (ANRO) Ends at 2.17, a -0.91 Surge/Plunge - DWinneX
ANROAlto Neuroscienc Latest Stock News & Market Updates - Stock Titan
Finanzdaten der Alto Neuroscience Inc-Aktie (ANRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):